-transparent.png){kind=logo}
The pooled results of 99 subjects from our Veterans Affairs population show that naltrexone-treated subjects had a greater reduction in alcohol craving, number of drinking days, and alcoholic relapse rates when compared with placebo-treated subjects. Based on our findings and results from other double-blind trials of naltrexone, we conclude that naltrexone is a safe and useful adjunct in the rehabilitation of alcohol-dependent patients. Increased baseline levels of psychological distress and craving as well as higher levels of somatic distress, anxiety, phobic anxiety, and obsessive-compulsive symptoms predicted an increased number of drinking days during the study. Significant interactions between naltrexone treatment, initial craving, and somatic distress suggest that naltrexone may be useful for subjects who present with high levels of craving and somatic symptoms.
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
January 1997,
Annual review of medicine,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
September 1997,
American family physician,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
January 2001,
The American journal on addictions,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
January 2003,
Journal of substance abuse treatment,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
June 2008,
Pharmacogenomics,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
January 1999,
Journal of psychoactive drugs,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
October 1996,
The Western journal of medicine,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
January 2009,
Alcoholism, clinical and experimental research,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
August 2002,
Revista clinica espanola,
J R Volpicelli, and
K L Clay, and
N T Watson, and
C P O'Brien
December 1998,
The Harvard mental health letter,
